FDA-approved biosimilar epoetin alfa
RETACRIT (retacrit.com) scores 66 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 13th percentile of 10846 Healthcare brands.
RETACRIT (epoetin alfa-epbx) is an FDA-approved biosimilar of Epogen/Procrit (epoetin alfa), used as a treatment option for anemia management. It is marketed to healthcare professionals through an HCP-focused website that provides information on its risks, benefits, safety, and efficacy data. RETACRIT is positioned as a clinically comparable alternative to existing reference biologic products for patients requiring anemia treatment under professional medical supervision.
| Brand Name | RETACRIT |
|---|---|
| Domain | retacrit.com |
| Industry | Healthcare |
| Main Competitors | Epogen (74/100), Procrit (61/100), Aranesp (69/100), Mircera (74/100) |
Moz Domain Authority 10/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Find info about RETACRIT® (epoetin alfa-epbx), an FDA-approved biosimilar of Epogen®/Procrit® (epoetin alfa), on the HCP site. See risks and benefits." (Meta description: 21 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:type, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on X (Twitter), Instagram; no detected presence on LinkedIn, Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is RETACRIT?", Claude could identify the brand as of September 2026. Retacrit is a biosimilar version of epoetin alfa, used to treat anemia caused by chronic kidney disease, chemotherapy, or certain other conditions by stimulating red blood cell production. It's manufactured by Pfizer and was one of the first epoetin biosimilars approved in the US Best known for Being an FDA-approved biosimilar to Epogen/Procrit (epoetin alfa) for treating anemia.
When asked "Best brands similar to RETACRIT?", Claude would recommend RETACRIT as of September 2026. It's a well-known, established biosimilar option in the erythropoiesis-stimulating agent category, so it would come up naturally in discussions of anemia treatment biosimilars.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
RETACRIT's main competitors in Healthcare: Epogen (74/100), Procrit (61/100), Aranesp (69/100), Mircera (74/100).
Sources: Brand Analyzer scan
RETACRIT (epoetin alfa-epbx) is an FDA-approved biosimilar medication of Epogen/Procrit (epoetin alfa), used for the management of anemia. It is a biologic product designed to be clinically comparable to its reference product in terms of safety and efficacy.
Sources: RETACRIT official site
RETACRIT has low AI-search visibility, scoring 21/100 on Brand Analyzer's AI visibility composite (visibility 13, trust 17, recommendation 40). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: RETACRIT official site
RETACRIT offers a single product: epoetin alfa-epbx, an FDA-approved biosimilar version of epoetin alfa, used for the treatment and management of anemia in appropriate patient populations.
Sources: RETACRIT official site
RETACRIT functions as a biosimilar treatment for anemia, providing healthcare professionals with an FDA-approved alternative to Epogen/Procrit for managing patients who require erythropoiesis-stimulating therapy.
Sources: RETACRIT official site
RETACRIT scores 40/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: RETACRIT official site
RETACRIT is an FDA-approved biosimilar, meaning it has undergone regulatory review demonstrating that it is clinically comparable to its reference product (Epogen/Procrit) in safety and efficacy. This FDA approval provides a basis for considering it a credible treatment option within the healthcare provider community.
Sources: RETACRIT official site
RETACRIT can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: RETACRIT official site
RETACRIT is used by healthcare professionals (HCPs), including physicians and other clinicians, who are involved in prescribing and managing anemia treatment for their patients.
Sources: RETACRIT official site
RETACRIT is known for being one of the first FDA-approved biosimilars of epoetin alfa, offering healthcare providers an alternative to the reference products Epogen and Procrit for anemia management.
Sources: RETACRIT official site
RETACRIT scores 21/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
RETACRIT has a weak AI-visibility profile at 21/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (40/100) and its weakest is visibility (13/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 10/100 and thin schema.org structured data. In a live check, Claude could already identify RETACRIT from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to RETACRIT: RESP Health (66/100), Reify Health (66/100), Richter's Clinic (66/100), 理化学研究所 (RIKEN) (66/100).
A step up - brands to learn from: ZT Corporate (71/100), Zorgnet-Icuro (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.